Clinical characteristics of the clopidogrel and ticagrelor or prasugrel groups.</p
Kaplan–Meier curve for net adverse cardiac event (NACE) in clopidogerl group and ticagrelor or prasu...
Characteristics of the major clinical subgroups and their healthy control counterparts.</p
<p>Comparison of clinical characteristics between the chemoradiotherapy group and the other therapy ...
Coronary angiographic findings and procedural characteristics of the clopidogrel and ticagrelor or p...
Complications during hospitalization of the clopidogrel and ticagrelor or prasugrel groups.</p
Clinical characteristics and immunosuppressive treatment of patients according to pathology groups.<...
Clinical outcomes in the clopidogrel and ticagrelor or prasugrel groups during a 3-year follow-up pe...
Baseline characteristics between the praziquantel and surgical treatment groups.</p
Baseline characteristics of the patients in the aleglitazar group compared with the placebo group.</...
<p>Baseline characteristics of clopidogrel-failure and clopidogrel-naïve patients.</p
<p>Clinical, demographic and laboratory characteristics of patients by diagnostic group.</p
Clinical characteristics of patients with only BC (BC group) and those with BC followed by TC (BC2TC...
<p>Clinical characteristics of the gastric hyperplastic polyps group and the control group.</p
Forest plot of exploratory subgroup analysis between clopidogrel group and ticagrelor or prasugrel g...
<p>Cardio-metabolic health and lifestyle characteristics of medication groups.</p
Kaplan–Meier curve for net adverse cardiac event (NACE) in clopidogerl group and ticagrelor or prasu...
Characteristics of the major clinical subgroups and their healthy control counterparts.</p
<p>Comparison of clinical characteristics between the chemoradiotherapy group and the other therapy ...
Coronary angiographic findings and procedural characteristics of the clopidogrel and ticagrelor or p...
Complications during hospitalization of the clopidogrel and ticagrelor or prasugrel groups.</p
Clinical characteristics and immunosuppressive treatment of patients according to pathology groups.<...
Clinical outcomes in the clopidogrel and ticagrelor or prasugrel groups during a 3-year follow-up pe...
Baseline characteristics between the praziquantel and surgical treatment groups.</p
Baseline characteristics of the patients in the aleglitazar group compared with the placebo group.</...
<p>Baseline characteristics of clopidogrel-failure and clopidogrel-naïve patients.</p
<p>Clinical, demographic and laboratory characteristics of patients by diagnostic group.</p
Clinical characteristics of patients with only BC (BC group) and those with BC followed by TC (BC2TC...
<p>Clinical characteristics of the gastric hyperplastic polyps group and the control group.</p
Forest plot of exploratory subgroup analysis between clopidogrel group and ticagrelor or prasugrel g...
<p>Cardio-metabolic health and lifestyle characteristics of medication groups.</p
Kaplan–Meier curve for net adverse cardiac event (NACE) in clopidogerl group and ticagrelor or prasu...
Characteristics of the major clinical subgroups and their healthy control counterparts.</p
<p>Comparison of clinical characteristics between the chemoradiotherapy group and the other therapy ...
DOI
Add to ORKG